Extended Data Fig. 8: Tumor IFN sensing inhibits NK cell cytotoxicity via upregulation of classical MHC-I.
From: In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer
a, Log fold change in the ratio of control (grey) or Tap1-null (purple) CT26 tumor cells transduced with Jak1 or control sgRNAs (n = 5 mice/group) cultured for 48 hours with activated NK cells at effector:target ratios of 0:1, 4:1 (p = 0.0319 [unpaired, two-sided Student’s t-test]), and 8:1 (p = 0.0189 [unpaired, two-sided Student’s t-test]), normalized to the 0:1 ratio for each condition. Data in bar plots are presented as mean ± SEM. b, Scatter plot of in vivo CT26 screening data showing average fold change by gene for the ICB vs NSG sub-genome-scale screen (x-axis) against the ICB + anti-asialo GM1 vs NSG screen (y-axis). Circle size is scaled to FDR in the ICB + anti-asialo GM1 vs NSG screen. *p < 0.05 (a).
